Physician profile
Manish Saran
NPI 1821208224
$11,008.63
in general payments reported to CMS, 2019-2025
29 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $921 · 2021: $1,078 · 2022: $1,481 · 2023: $1,804 · 2024: $2,095 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,094.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,603.66 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $1,121.68 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $964.12 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $805.96 | 2019-2025 | Rexulti, Brintellix |
| Teva Pharmaceuticals USA, INC. | $739.55 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $690.30 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $664.67 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $627.33 | 2020-2025 | Caplyta |
| Corium, LLC | $589.50 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $512.17 | 2019-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $456.53 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $436.74 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $265.26 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $197.32 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $186.41 | 2025 | Jornay Pm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $164.98 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $151.81 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $146.60 | 2019-2024 | Dyanavel Xr, Onyda Xr |
| Shire North American Group INC | $139.15 | 2019 | |
| Zoll Respicardia, INC. | $132.04 | 2021 | |
| Axsome Therapeutics, INC. | $102.72 | 2023-2025 | Auvelity |
| Sage Therapeutics, LLC | $72.90 | 2022-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $67.03 | 2023-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $61.23 | 2019-2020 | |
| Bausch Health US, LLC | $31.77 | 2022-2023 | Wellbutrin, Aplenzin |
| Avanir Pharmaceuticals, INC. | $28.79 | 2019-2020 | |
| Indivior INC. | $18.45 | 2024 | Perseris |
| Eisai INC. | $15.13 | 2020 | |
| Neos Therapeutics, LP | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Saran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.